Cortexyme to merge with Novosteo; to issue ~6M shares, appoints Novosteo CEO as CEO

Quince Therapeutics, Inc.

Enters definitive agreement to acquire Novosteo via reverse merger; expects to issue ~6M shares in transaction.
Post-merger pro forma cash, cash equivalents and investments of ~$120M as of March 31, 2022.
Dirk Thye, MD (Novosteo CEO) to become Cortexyme CEO; Chris Lowe steps down as interim CEO but remains CFO/COO.
Philip Low, PhD appointed to Cortexyme board; independent board approves 4,000,000-share inducement plan for new hires.
Closing expected within 30 days, subject to Novosteo stockholder approval and other customary conditions.

item 1.01 item 2.02 item 3.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dirk Thye

Chief Executive Officer

QNCX · Quince Therapeutics, Inc.

Filed: May 12, 2022, 7:59 PM ET

the appointment of Dirk Thye, M.D. as the Chief Executive Officer of the Company and as principal executive officer and a Class II director of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dirk Thye was appointed as Chief Executive Officer at Quince Therapeutics, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

the appointment of Dirk Thye, M.D. as the Chief Executive Officer of the Company and as principal executive officer and a Class II director of the Company

View on SEC.gov

Quince Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-148822

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.